



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

BRD2492

Cat. No.:	HY-124053
CAS No.:	1821669-43-5
Molecular Formula:	C ₂₀ H ₁₈ N ₄ O ₂
Molecular Weight:	346.38
Target:	HDAC
Pathway:	Cell Cycle/DNA Damage; Epigenetics
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 31.25 mg/mL (90.22 mM; ultrasonic and warming and heat to 60°C)

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		2.8870 mL	14.4350 mL	28.8700 mL
	5 mM		0.5774 mL	2.8870 mL	5.7740 mL
	10 mM		0.2887 mL	1.4435 mL	2.8870 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

BRD2492 (compound 6d) is a potent, selective HDAC1 and HDAC2 inhibitor with IC₅₀s of 13.2 nM and 77.2 nM, respectively. BRD2492 exhibits >100-fold selectivity for HDAC1/2 over selectivity over HDAC3 and HDAC6. BRD2492 inhibits breast cancer cell lines growth with IC₅₀s of 1.01 μM and 11.13 μM for T-47D and MCF-7 cells, respectively^[1].

IC₅₀ & Target

HDAC1 13.2 nM (IC ₅₀)	HDAC2 77.2 nM (IC ₅₀)	HDAC3 8908 nM (IC ₅₀)	HDAC6 >1000 nM (IC ₅₀)
--------------------------------------	--------------------------------------	--------------------------------------	---------------------------------------

REFERENCES

[1]. Linda Schäker-Hübner, et al. Balancing Histone Deacetylase (HDAC) Inhibition and Drug-likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors. ChemMedChem. 2022 May 4;17(9):e202100755.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA